Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:51:58.939Z.
Calculation as of: 2026-10-06T16:51:58.939Z.
Quote observation: 2026-10-06T16:50:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$142.35M
Price/FCF Ratio
N/A
TTM Avg
34.10
3Y Avg
34.10
5Y Avg
34.10
Market Cap
$144.56M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$139.73M
Price/FCF Ratio
1.11
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$147.71M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.27M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $143.03M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $142.35M | N/A | 34.10 | 34.10 | 34.10 |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.56M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 1.11 | 4.90 | 4.90 | 4.90 |
| Alpha Cognition Inc (ACOG)vs › | $139.16M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $147.71M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | N/A | 177.92 | 1258.54 | 1258.54 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.77M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
